However, the data in the Catalogue of Somatic Mutations in Cancer (COSMIC) indicate that 41.6% (2463 of 5926) of the CRC patients contain KRAS or BRAF mutant genes [25, 26], suggesting that a large population of CRC patients can not profit from the anti-EGFR treatment and new therapeutic strategies are urgently needed. Here, EGFR is linked to colorectal carcinoma.